Karo Pharma AB (KARO.ST)
21 Jun 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Karo Pharma Determines Terms For Rights Issue
- BRIEF-Karo Pharma Q1 EBITDA rose to SEK 89 mln
- BRIEF-Karo Pharma: Board Of Directors Resolves On Fully Guaranteed Rights Issue
- BRIEF-Karo Pharma Intends To Propose Dividend Of SEK 0.30 Per Share
- BRIEF-Karo Pharma Acquires Major Product Portfolio for EUR 260 Mln